OLD Second National Bank of Aurora Buys New Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

OLD Second National Bank of Aurora purchased a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,410 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.

A number of other hedge funds also recently bought and sold shares of the business. Assenagon Asset Management S.A. purchased a new stake in Amicus Therapeutics during the second quarter valued at approximately $8,386,000. M&G Plc lifted its position in Amicus Therapeutics by 12.4% in the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after buying an additional 82,728 shares during the last quarter. Edgestream Partners L.P. boosted its stake in Amicus Therapeutics by 1,290.4% during the first quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock worth $3,183,000 after buying an additional 250,734 shares during the period. CANADA LIFE ASSURANCE Co increased its position in Amicus Therapeutics by 7.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after acquiring an additional 7,304 shares during the last quarter. Finally, Fiera Capital Corp raised its stake in shares of Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after acquiring an additional 58,113 shares during the period.

Amicus Therapeutics Trading Down 1.1 %

FOLD opened at $10.37 on Thursday. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The stock’s fifty day moving average is $11.07 and its two-hundred day moving average is $10.61. The company has a market capitalization of $3.10 billion, a P/E ratio of -30.50 and a beta of 0.68. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57.

Insider Buying and Selling

In other news, CEO Bradley L. Campbell sold 7,901 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $11,083,175. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $9,398,532.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,401 shares of company stock valued at $352,038 over the last three months. 2.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Cantor Fitzgerald lifted their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price objective for the company. Morgan Stanley cut their target price on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Guggenheim boosted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.